Coliseum Capital Management, managed by Christopher Shackelton and Adam Gray, yesterday filed for its insider transaction in Insite Vision Inc. (INSV). The filing reveals that Coliseum Capital Management sold 451 thousand shares in INSV on December 13th, at $0.45 per share. After that, the firm still had 14.40 million shares in its position. INSV is trading in OTC market, and Coliseum Capital Management did not report it in its third quarter 13F filing. The stock is now priced at $0.43, and has increased by 23% year to date.
Coliseum Capital Management is a privately owned hedge fund. The firm invests in public equity markets. The firm is based in New York City, New York. The firm has a portfolio of $107 million, mainly invested in Services, Financial, and Healthcare sector.
Per Google Finance, InSite Vision Incorporated “is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company’s portfolio of ophthalmic pharmaceutical products is based on DuraSite drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a variety of drug candidates. It is focusing its research, development and commercial support efforts on topical products formulated with its DuraSite drug delivery technology.”